LONDON, June 21. / TASS /. The drug sotrovimab (VIR-7831) for the treatment of COVID-19, which was created by the British pharmaceutical company GSK (GlaxoSmithKline) and its American partner Vir Biotechnology, significantly reduces the risk of hospitalization or death of adult outpatients with an increased risk of complications. This is stated in a press release published on Monday by GSK.
“GlaxoSmithKline and Vir Biotechnology today announced definitive, confirming results from a Phase III study showing that sotrovimab significantly reduces the risk of hospitalization or death in high-risk adult outpatients with mild to moderate coronavirus infection,” the document says. It clarifies that the drug showed a 79% decrease in the number of hospitalizations or deaths among patients.
VIR-7831 is an antiviral drug based on one type of monoclonal antibodies – cloned molecules produced by the immune system and capable of binding and neutralizing the causative agent of a certain disease. In March, drug developers reported that covid patients tolerate intravenous therapy well.
At the end of May, the use of the drug was approved in the United States, and at the beginning of June in the UAE and Kuwait. On May 7, the European Medicines Agency began the examination of this drug.
GSK and Vir are also testing another monoclonal antibody, VIR-7832, which should boost T-cell immunity in COVID-19.
See also: All about the coronavirus: a selection of relevant materials